Policyholder Services

Am I covered to inject Kybella for the treatment of double chins?

Updated 5/29/2018

Coverage for this procedure is included under OMIC’s Surgery Class 1 rating classification.

Kybella (formerly known as ATX-101) is an injectable drug made from deoxycholic acid.  In April 2015, the FDA approved Kybella as a treatment for adults with moderate to severe fat below the chin. The safety and effectiveness of Kybella for treatment of submental fat were established in two large clinical trials. Use of Kybella for the treatment of fat outside of the submental area is neither approved nor recommended by the FDA.



Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

#1. Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $20 Million to our members through dividends.